Literature DB >> 27869811

Diffuse large B-cell lymphoma: the challenge of relapse after an autologous stem cell transplant.

S P Robinson1.   

Abstract

Mesh：

Year:  2016        PMID： 27869811     DOI： 10.1038/bmt.2016.292

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  11 in total

1.  Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12.

Authors:  Michael Crump; John Kuruvilla; Stephen Couban; David A MacDonald; Vishal Kukreti; C Tom Kouroukis; Morel Rubinger; Rena Buckstein; Kevin R Imrie; Massimo Federico; Nicola Di Renzo; Kang Howson-Jan; Tara Baetz; Leonard Kaizer; Michael Voralia; Harold J Olney; A Robert Turner; Jonathan Sussman; Annette E Hay; Marina S Djurfeldt; Ralph M Meyer; Bingshu E Chen; Lois E Shepherd
Journal:  J Clin Oncol       Date:  2014-09-29       Impact factor: 44.544

2.  Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European society for blood and marrow transplantation.

Authors:  S Dietrich; H Finel; C Martinez; J Tischer; D Blaise; P Chevallier; L Castagna; N Milpied; A Bacigalupo; P Corradini; M Mohty; M Sanz; A Hausmann; S Montoto; S Robinson; A Boumendil; A Sureda; P Dreger
Journal:  Leukemia       Date:  2016-05-05       Impact factor: 11.528

3.  Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study.

Authors:  E Van Den Neste; N Schmitz; N Mounier; D Gill; D Linch; M Trneny; R Bouadballah; J Radford; M Bargetzi; V Ribrag; U Dührsen; D Ma; J Briere; C Thieblemont; E Bachy; C H Moskowitz; B Glass; C Gisselbrecht
Journal:  Bone Marrow Transplant       Date:  2016-09-19       Impact factor: 5.483

4.  Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.

Authors:  Laurie H Sehn; Jane Donaldson; Mukesh Chhanabhai; Catherine Fitzgerald; Karamjit Gill; Richard Klasa; Nicol MacPherson; Susan O'Reilly; John J Spinelli; Judy Sutherland; Kenneth S Wilson; Randy D Gascoyne; Joseph M Connors
Journal:  J Clin Oncol       Date:  2005-06-13       Impact factor: 44.544

5.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.

Authors:  T Philip; C Guglielmi; A Hagenbeek; R Somers; H Van der Lelie; D Bron; P Sonneveld; C Gisselbrecht; J Y Cahn; J L Harousseau
Journal:  N Engl J Med       Date:  1995-12-07       Impact factor: 91.245

6.  Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry.

Authors:  Roel J W van Kampen; Carmen Canals; Harry C Schouten; Arnon Nagler; Kirsty J Thomson; Jean-Paul Vernant; Agnes Buzyn; Marc A Boogaerts; Jian-Jian Luan; Sébastien Maury; Noel J Milpied; Jean-Pierre Jouet; Gert J Ossenkoppele; Anna Sureda
Journal:  J Clin Oncol       Date:  2011-02-14       Impact factor: 44.544

7.  Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma.

Authors:  Christian Gisselbrecht; Norbert Schmitz; Nicolas Mounier; Devinder Singh Gill; David C Linch; Marek Trneny; Andre Bosly; Noel J Milpied; John Radford; Nicolas Ketterer; Ofer Shpilberg; Ulrich Dührsen; Hans Hagberg; David D Ma; Andreas Viardot; Ray Lowenthal; Josette Brière; Gilles Salles; Craig H Moskowitz; Bertram Glass
Journal:  J Clin Oncol       Date:  2012-10-22       Impact factor: 44.544

8.  Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party.

Authors:  S P Robinson; A Boumendil; H Finel; D Blaise; X Poiré; E Nicolas-Virelizier; R Or; R Malladi; A Corby; L Fornecker; D Caballero; D Pohlreich; A Nagler; C Thieblemont; J Finke; E Bachy; L Vincent; W Schroyens; H Schouten; P Dreger
Journal:  Bone Marrow Transplant       Date:  2015-11-30       Impact factor: 5.483

9.  Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis.

Authors:  Nilanjan Ghosh; Reem Karmali; Vanderson Rocha; Kwang Woo Ahn; Alyssa DiGilio; Parameswaran N Hari; Veronika Bachanova; Ulrike Bacher; Parastoo Dahi; Marcos de Lima; Anita D'Souza; Timothy S Fenske; Siddhartha Ganguly; Mohamed A Kharfan-Dabaja; Tim D Prestidge; Bipin N Savani; Sonali M Smith; Anna M Sureda; Edmund K Waller; Samantha Jaglowski; Alex F Herrera; Philippe Armand; Rachel B Salit; Nina D Wagner-Johnston; Ephraim Fuchs; Javier Bolaños-Meade; Mehdi Hamadani
Journal:  J Clin Oncol       Date:  2016-06-06       Impact factor: 44.544

10.  Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma.

Authors:  Kirsty J Thomson; Emma C Morris; Adrian Bloor; Gordon Cook; Don Milligan; Anne Parker; Fiona Clark; Lynny Yung; David C Linch; Ronjon Chakraverty; Karl S Peggs; Stephen Mackinnon
Journal:  J Clin Oncol       Date:  2008-12-08       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.